COR2ED - Oncology Medical Conversation

By COR2ED Medical EducationScience Medicine Health & Fitness Education Courses

COR2ED - Oncology Medical Conversation episodes

October 15Metastatic TNBC cannot wait
In this video podcast, Prof. Giuseppe Curigliano and Dr Javier Cortés explore how TROP2-directed antibody–drug conjugates (ADCs) are shaping 1st line treatment for metastatic triple-negative breast cancer (TNBC).
Key clinical takeaways:
Earlier placement: TROPION-Breast02 and ASCENT-03 support 1st line TROP2 ADC use in defined patients who are not candidates for an ICI; ASCENT-04 supports SG plus pembrolizumab in the studied PD-L1-positive population 
Individualised selection: Apply each trial to the appropriate patient. Consider disease characteristics, prior therapy, schedule and AE profile; avoid indirect comparisons between Dato-DXd and SG 
Proactive safety: Translate the Dato-DXd and SG safety evidence into treatment-specific prevention, monitoring and escalation plans before dose 1 
You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/breast-cancer-connect/programmes/metastatic-tnbc
Or watch on YouTube: https://youtu.be/3gr7g_IeRtU
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/breastcancerconnect/home/
X: https://x.com/BreastCaConnect
Instagram: https://www.instagram.com/cor2edmeded 

Subscribe to this channel to stay up to date with new medical education programmes as they’re released.

This content is intended for healthcare professionals only.
This podcast is supported by an Independent Education Grant from AstraZeneca

This podcast is developed by cor2ed.com
Published on October 2026
28 min
March 12Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer
Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer

Key clinical takeaways:
Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multidisciplinary collaboration. Pathologists are central to this process to ensure accurate interpretation and optimal patient management
Incorporating HER2-low and HER2-ultralow categories in biomarker testing is critical for mBC due to the demonstrated efficacy of HER2-targeted antibody-drug conjugates, such as trastuzumab deruxtecan, in these patient subsets, expanding therapeutic options beyond traditional HER2-positive cases
High-quality pre-analytical handling and nuanced interpretation are essential for accurate HER2 classification, particularly for HER2-low and –ultralow disease. Small errors in testing or interpretation can lead to missed treatment opportunities.

This is the full video. Watch the shorter highlights video here: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=0

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying one-page snapshot: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=2

Follow us on social media:
LinkedIn: https://linkedin.com/company/ntrk-connect
X: https://x.com/PresOnc_Connect

This content is intended for healthcare professionals only.
This video is supported by an Independent Education Grant from Daiichi Sankyo.

This video is developed by cor2ed.com
Published on March 2026.

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
24 min
December 17, 2025Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification
Understanding HER2-low and HER2-ultralow classification in mBC

In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice.
The experts explore:
Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework
The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template
When and why to perform re-biopsy to detect changes in HER2 expression over time
Best practices for monitoring and managing T-DXd–related adverse events, including nausea, vomiting, fatigue and ILD/pneumonitis

Watch now to deepen your understanding of HER2-low and HER2-ultralow classification, refine how and when you test, and appreciate the impact on therapeutic decision-making in mBC.

Clinical takeaways
DESTINY-Breast04 and DESTINY-Breast-06 established T-DXd as an effective option for HER2-low and HER2-ultralow mBC, improving PFS and OS and showing that even minimal HER2 expression can identify patients who benefit from T-DXd
Current CAP reporting template separates HER2-low (IHC 1+ or 2+/ISH–) and HER2-ultralow (IHC 0 with faint or incomplete membrane staining in ≤10% of tumour cells) from true HER2-0, creating treatment-defining strata for HER2-targeted ADCs such as T-DXd
Because HER2 expression is dynamic between primary and metastatic sites and over time, re-biopsy at progression, particularly in tumours previously scored as HER2-0, should be considered to identify new candidates for T-DXd
T-DXd delivers substantial antitumour activity, but treatment-related adverse events, including nausea, vomiting, fatigue, alopecia and, in particular, ILD/pneumonitis, require careful and proactive management. Clinicians should apply structured supportive care and early, vigilant monitoring to ensure safe and sustained treatment

This is the full video. Watch the shorter highlights video here: https://youtu.be/3xepcF70Ljw

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website

Follow us on social media:
LinkedIn: https://www.linkedin.com/company/breastcancerconnect/
X: https://x.com/BreastCaConnect

This content is intended for healthcare professionals only.

This programme is supported by an Independent Education Grant from AstraZeneca.
This podcast is developed by cor2ed.com

Published December 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
26 min
November 07, 2025Understanding EP-NEC: Through Diagnosis, Treatment, and Support
In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.
They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.
Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease.
Key clinical takeaways:
Unlike NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers, with a need for more effective treatments
While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise
Accessing a support network can provide emotional reinforcement and information for patients and their care partners

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0
Or watch on YouTube: https://youtu.be/nfng2s3jSw8
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true
X:https://x.com/net_connectinfo
This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.
This podcast is developed by cor2ed.com
Published in November 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
28 min
September 30, 2025Exploring the role of targeted radiopharmaceutical treatment in NETs
How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?
In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.
As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy.
Key clinical takeaways:
Pair the right patient with the right treatment using an understanding of the key clinical studies
The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data
The best outcomes are achieved through multi-disciplinary collaborations that include the patient

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0

Follow us on social media:
LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true
X: https://x.com/net_connectinfo
This content is intended for healthcare professionals only.
This podcast is supported by an Independent Education Grant from ITM.
This podcast is developed by cor2ed.com

Published September 2025
22 min
September 17, 2025Exploring the role of targeted radiopharmaceutical treatment in NETs
How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?
In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.
As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy.
Key clinical takeaways:
Pair the right patient with the right treatment using an understanding of the key clinical studies
The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data
The best outcomes are achieved through multi-disciplinary collaborations that include the patient

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0

Follow us on social media:
LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true
X: https://x.com/net_connectinfo
This content is intended for healthcare professionals only.
This podcast is supported by an Independent Education Grant from ITM.
This podcast is developed by cor2ed.com

Published September 2025
22 min
May 19, 2025Tackling mPDAC: chemotherapy strategies that matter
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.
This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line.
Key clinical takeaways:
mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with advanced-stage disease and require treatment with chemotherapy as soon as possible
Frontline regimens should be individualised based on performance status, comorbidities, and risk of neuropathy; FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles
Choice of 2nd line treatment should be guided by prior regimen and patient fitness
Dose modification and alternative scheduling are standard in real-world practice and are used to maintain dose intensity while improving tolerability and reducing adverse events
You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0
Or watch on YouTube: https://youtu.be/8YxRnjOYUv4
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/giconnect
X: https://x.com/giconnectInfo
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Ipsen USA.
This podcast is developed by cor2ed.com
Published May 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
22 min
May 14, 2025 Understanding Rare NSCLC Mutations: Insights, access and support
Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.
As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.
Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey.
What does the patient pathway look like from both perspectives? What are the needs of Medical Oncologists and patients when navigating the treatment journey? What do patients need from their oncologists? What do oncologists think their patients need from them? Are these needs matched by the support currently available?
You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/understanding-rare-nsclc-mutations/?media=0
Or watch on YouTube: https://www.youtube.com/watch?v=Z57cUtQx1BE&t

Follow LUNG CONNECT on social media:
X – https://x.com/lung_connect
LinkedIn – https://www.linkedin.com/company/lungconnect/
This content is intended for healthcare professionals only.
The experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.

This podcast is developed by cor2ed.com
Published on May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
21 min
April 28, 2025The HER2 diagnostic and treatment landscape in NSCLC
Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC
This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.
In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC.
The conversation unfolds to cover;
How to distinguish HER2 alterations from other alterations on biomarker reports
The latest efficacy and safety data of currently approved and emerging treatments for HER2-altered NSCLC
The potential CNS activity of these treatments in patients with HER2-mutated NSCLC
How the treatment pathway may look in the near future
You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-2/
Or watch on YouTube: https://youtu.be/E8-3GDyJT9Y

Follow LUNG CONNECT on social media:
X – https://x.com/lung_connect
LinkedIn – https://www.linkedin.com/company/lungconnect/
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Bayer.

This podcast is developed by cor2ed.com
Published on May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
19 min
April 15, 2025The HER2 Diagnostic and Treatment Landscape in NSCLC
Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives
This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.
What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos.
In this episode the discussion focuses identifying HER2-directed NSLC, considering mutations, overexpression and amplifications, whilst not forgetting how best practice in identification of HER2 alterations may be translated in the community setting.
Listen to different expert perspectives on
The different HER2 alterations and prevalence in NSCLC
Which technique to identify which HER2 alteration
HER2-targeted treatments, both approved and in development

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-1/?media=1
Or watch on YouTube: https://youtu.be/3vMCzR1jqbI

Follow LUNG CONNECT on social media:
X – https://x.com/lung_connect
LinkedIn – https://www.linkedin.com/company/lungconnect/

This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Bayer.

This podcast is developed by cor2ed.com
Published on April 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
22 min

About COR2ED - Oncology Medical Conversation

From the publisher's feed

Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy.

Share COR2ED - Oncology Medical Conversation

Sign up to save your podcasts

COR2ED - Oncology Medical Conversation

COR2ED - Oncology Medical Conversation episodes

About COR2ED - Oncology Medical Conversation